Set for multiple late-stage readouts in oncology in 2026, BioNTech is entering a crucial phase of its roadmap beyond Covid-19 ...

Researchers found that in mouse models (in a lab), SARS‑CoV‑2 mRNA vaccination triggered strong type I interferon signals, ...

The vaccines subsector received a big fillip from Covid, but its potential extends far beyond combating pandemics. Dr Mike ...

Changing just one atom in a COVID-19 vaccine lipid redirects delivery from the liver to the spleen, improving tumor suppression in mice. The dominant ionizable lipids in approved vaccines attract ...

The firm is expecting a slew of key readouts for mRNA vaccines for treating cancer and rare diseases and is exploring vaccines for autoimmune conditions.

Scientists and clinicians reported advances that addressed conditions once thought irreversible, from congenital deafness and rare mitochondrial disorders to cancers that have long resisted treatment.

BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and mRNA immunotherapiesExpected 2026 oncology ...

South Florida scientists are developing innovative ways to use RNA technology to destroy cancer cells, but uncertainty over ...

Pancreatic cancer uses a sugar-coated disguise to evade the immune system, helping explain why it’s so hard to treat.